Celltrion said on the 19th that its autoimmune disease therapy Remsima SC (ingredient infliximab; U.S. brand name "Zymfentra") showed treatment efficacy in a post-hoc analysis of a phase 3 clinical trial in patients with Crohn's disease or ulcerative colitis. The results will be unveiled at the European Crohn's and Colitis Organisation (ECCO).
Remsima SC, developed by converting the Remsima intravenous (IV) formulation to a subcutaneous (SC) injection, is a key product that accounts for about 45% (1.8889 trillion won) of Celltrion's total sales.
Marking its 21st year, 2026 ECCO is a leading academic conference in inflammatory bowel disease (IBD), held in Stockholm, Sweden, from the 18th to the 21st (local time). Celltrion will be the only domestic corporations to run a standalone promotional booth and will hold a symposium and poster presentations.
According to the post-hoc analysis to be released on the first day of the conference, when a 240 mg infliximab subcutaneous injection was administered to a patient group that had discontinued infliximab intravenous therapy and received a placebo for at least 16 weeks, most patients showed a rapid recovery of clinical response. Efficacy and safety were stably maintained through the 102-week follow-up.
The company said that, given that treatment gaps frequently occur in IBD patients for clinical and nonclinical reasons, the results suggests the strategic utility of infliximab SC administration after treatment interruption.
At the symposium, under the theme "Improving patient care with the infliximab SC formulation," discussions will be held on treatment optimization based on real-world clinical data. Expert sessions at the booth will present ▲ the clinical significance of ultra-long-term outcomes after switching from IV to SC ▲ the need for combination therapy with tumor necrosis factor-alpha (TNF-α) inhibitors in IBD treatment ▲ insights on switch therapy based on real-world clinical data from Northern Europe.
Celltrion emphasized that it is the only corporations to have launched all infliximab formulations—IV lyophilized, IV high-concentration liquid, and SC. The recently approved IV high-concentration liquid formulation reduces compounding time and staffing needs, improving efficiency in clinical settings, and the company expects it to help expand Remsima prescriptions.
The company plans to expand treatment options for autoimmune diseases through a portfolio of four IBD therapies, including Remsima and Remsima SC, as well as Yuflyma and Steqeyma.
A Celltrion official said, "We consistently present prescribing evidence data at ECCO every year," adding, "We will enhance our competitiveness in autoimmune disease therapies and strengthen our market position by developing innovative formulations."